283 related articles for article (PubMed ID: 28128200)
1. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma.
Sheppard S; Guedes J; Mroz A; Zavitsanou AM; Kudo H; Rothery SM; Angelopoulos P; Goldin R; Guerra N
Nat Commun; 2017 Jan; 8():13930. PubMed ID: 28128200
[TBL] [Abstract][Full Text] [Related]
2. Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA.
Wan LL; Zhang DQ; Zhang JN; Ren LQ
J Zhejiang Univ Sci B; 2017 Jun; 18(6):522-531. PubMed ID: 28585428
[TBL] [Abstract][Full Text] [Related]
3. Chronic Alcohol Consumption Promotes Diethylnitrosamine-Induced Hepatocarcinogenesis via Immune Disturbances.
Yan G; Wang X; Sun C; Zheng X; Wei H; Tian Z; Sun R
Sci Rep; 2017 May; 7(1):2567. PubMed ID: 28566719
[TBL] [Abstract][Full Text] [Related]
4. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.
Schneider C; Teufel A; Yevsa T; Staib F; Hohmeyer A; Walenda G; Zimmermann HW; Vucur M; Huss S; Gassler N; Wasmuth HE; Lira SA; Zender L; Luedde T; Trautwein C; Tacke F
Gut; 2012 Dec; 61(12):1733-43. PubMed ID: 22267597
[TBL] [Abstract][Full Text] [Related]
5. Extracellular ATP and Purinergic P2Y
Schulien I; Hockenjos B; van Marck V; Ayata CK; Follo M; Thimme R; Hasselblatt P
Cancer Res; 2020 Feb; 80(4):699-708. PubMed ID: 31822494
[TBL] [Abstract][Full Text] [Related]
6. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
7. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
8. The Paradoxical Role of NKG2D in Cancer Immunity.
Sheppard S; Ferry A; Guedes J; Guerra N
Front Immunol; 2018; 9():1808. PubMed ID: 30150983
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic measles virus enhances antitumour responses of adoptive CD8
Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
Bugide S; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
[TBL] [Abstract][Full Text] [Related]
12. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Song JS; Chang CC; Wu CH; Dinh TK; Jan JJ; Huang KW; Chou MC; Shiue TY; Yeh KC; Ke YY; Yeh TK; Ta YN; Lee CJ; Huang JK; Sung YC; Shia KS; Chen Y
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753481
[TBL] [Abstract][Full Text] [Related]
13. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
14. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.
Kamimura H; Yamagiwa S; Tsuchiya A; Takamura M; Matsuda Y; Ohkoshi S; Inoue M; Wakai T; Shirai Y; Nomoto M; Aoyagi Y
J Hepatol; 2012 Feb; 56(2):381-8. PubMed ID: 21756848
[TBL] [Abstract][Full Text] [Related]
15. NKG2D and its ligands: key to immunotherapy of liver cancer?
Mondelli MU
J Hepatol; 2012 Feb; 56(2):308-10. PubMed ID: 21798219
[No Abstract] [Full Text] [Related]
16. [NKG2D CAR-T cells as an immunotherapy in hepatocellular carcinoma].
Roussine Codo G; Khennas S
Med Sci (Paris); 2020; 36(6-7):662-664. PubMed ID: 32614319
[No Abstract] [Full Text] [Related]
17. Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.
Subleski JJ; Scarzello AJ; Alvord WG; Jiang Q; Stauffer JK; Kronfli A; Saleh B; Back T; Weiss JM; Wiltrout RH
J Hepatol; 2015 Nov; 63(5):1181-9. PubMed ID: 26143441
[TBL] [Abstract][Full Text] [Related]
18. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
19. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
20. NKG2D ligand RAE1ε induces generation and enhances the inhibitor function of myeloid-derived suppressor cells in mice.
Qian L; Liu Y; Wang S; Gong W; Jia X; Liu L; Ye F; Ding J; Xu Y; Fu Y; Tian F
J Cell Mol Med; 2017 Sep; 21(9):2046-2054. PubMed ID: 28276625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
